News GW Pharma tops list of UK R&D spenders Pharma is leading the way in R&D investment in the UK, with cannabis medicine specialist GW splurging almost 1,345% of its total revenue on research according to an analysis.
News Reaction to MSD's UK exit as government tries to renew talks The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face